首页> 外文期刊>Internal medicine. >Outcome of ANCA-associated primary renal vasculitis in Miyazaki Prefecture.
【24h】

Outcome of ANCA-associated primary renal vasculitis in Miyazaki Prefecture.

机译:宫崎县与ANCA相关的原发性肾血管炎的结果。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECT: We examined the prognosis of patients with onset of new primary renal vasculitis (PRV) in Miyazaki Prefecture. PATIENTS AND METHODS: We enrolled and followed-up 56 patients (age, 70.4 +/- 10.9 years, mean +/- SD) with onset of new PRV between January 2000 and December 2004, for a median of 24 months. Patients with PRV were defined according to the EUVAS (European Systemic Vasculitis Study Group) criteria. Outcome and factors predicting unfavorable outcome of death were examined. RESULTS: Among the patients, 25% (n=14) required dialysis therapy immediately at the start of immunosuppressive therapy and of these, renal function recovered in only 3 and 6 died during the first admission. On the other hand, 75% (n=42) did not require immediate dialysis, but 8 patients were introduced to dialysis therapy thereafter. At the end of follow-up, 26 (46%) had survived without dialysis, 10 (18%) were dependent on dialysis and 20 (36%) had died. Infection was the major cause of death (n=11) . The Cox proportional hazards model showed that the presence of lung lesions and immediate dialysis therapy conferred poorer survival rates (HR, 3.32, 95% CI, 1.14 to 9.71; HR 2.73, 95% CI, 1.03 to 7.23, respectively). CONCLUSION: A poor survival rate is independently associated with the presence of lung lesions and advanced renal failure at the start of immunosuppressive therapy in patients with PRV. Half of the deaths were due to infection. Thus, PRV should be identified at an early stage and the treatment protocol should prevent infectious complications. These measures should improve the prognosis of patients with PRV.
机译:目的:我们检查了宫崎县新发原发性肾血管炎(PRV)患者的预后。患者与方法:我们纳入并随访了2000年1月至2004年12月之间新PRV发作的56例患者(年龄70.4 +/- 10.9岁,平均+/- SD),平均随访24个月。 PRV患者是根据EUVAS(欧洲系统性血管炎研究组)标准定义的。检查了预后不良的结果和因素。结果:在这些患者中,有25%(n = 14)在开始免疫抑制治疗后立即需要透析治疗,其中,只有3例和6例在首次入院时死亡的肾功能得以恢复。另一方面,有75%(n = 42)的患者不需要立即透析,但随后有8位患者接受了透析治疗。随访结束时,有26名(46%)无需透析而存活,有10名(18%)依赖透析而死亡,有20名(36%)死亡。感染是主要的死亡原因(n = 11)。 Cox比例风险模型显示,存在肺部病变和立即进行透析治疗会降低生存率(HR,3.32、95%CI,1.14至9.71; HR 2.73、95%CI,1.03至7.23)。结论:PRV患者开始免疫抑制治疗后,不良的生存率与肺部病变的存在和晚期肾功能衰竭有关。一半的死亡是由于感染。因此,应及早发现PRV,治疗方案应防止感染并发症。这些措施应改善PRV患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号